Volume 2.13 | Apr 8

Mammary Cell News 2.13 April 8, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

Pathways that Can Repair BRCA1 Cancer Gene Mutation Clarified in Mice
In a new study in mice, scientists have compensated for mutations in the BRCA1 gene that can lead to cancer by deleting a second gene, which then lessens the probability of cancer. [Press release from National Institutes of Health discussing online prepublication in Cell]

Watch Procedure Now  
Obtain high quality mammary tumorspheres
with MammoCult®

by STEMCELL Technologies
 
 
CLICK HERE TO LEARN MORE STEMCELL Technologies Inc
 



SCIENCE NEWS

Study Links Chemical Exposure to Breast Cancer
Exposure to certain chemicals and pollutants before a woman reaches her mid-30s could treble her risk of developing breast cancer after the menopause. [Press release from Reuters discussing online prepublication in Occupational and Environmental Medicine]

How Breast Cancer Cells Evade Therapeutic Attacks
This study reveals how cancer cells become impervious to the anti-estrogen drugs such as tamoxifen by activating a specific biochemical cascade. [Press release from EurekAlert! discussing online prepublication in Genes & Development]

Zoledronic Acid Reduces Spread of Cancer Cells in Women Undergoing Chemotherapy for Locally Advanced Breast Cancer
Research reports that zoledronic acid, which is a bone strengthening drug, when given together with chemotherapy might decrease the spread of cancer in women with locally advanced breast cancer. [Press release from Medical News Today discussing online prepublication in The Lancet Oncology]

Breast Cancer Patients with BRCA Gene Mutations are Four Times More Likely to Get Cancer in Opposite Breast
Women with breast cancer before age 55 who carry an inherited mutation in the breast cancer susceptibility genes BRCA1 or BRCA2 are four times more likely to develop cancer in the breast opposite to their initial tumor as compared to breast cancer patients without these genetic defects. [Press release from Fred Hutchinson Cancer Research Center discussing online prepublication in Journal of Clinical Oncology]

ALDEFLUORBreastCancer_645x110_v02



CURRENT PUBLICATIONS

LABORATORY RESEARCH

53BP1 Inhibits Homologous Recombination in BRCA1-Deficient Cells by Blocking Resection of DNA Breaks
Here, researchers show that DNA breaks in BRCA1-deficient cells are aberrantly joined into complex chromosome rearrangements by a process dependent on the nonhomologous end-joining factors 53BP1 and DNA ligase 4. [Cell]

CARM1 Mediates the Ligand-Independent and Tamoxifen-Resistant Activation of the Estrogen Receptor Alpha by cAMP
Sustained protein kinase A activity promoting a constitutive interaction may contribute to tamoxifen resistance of breast tumors. [Genes Dev]

Key Roles for MED1 LxxLL Motifs in Pubertal Mammary Gland Development and Luminal-Cell Differentiation
Results establish a key nuclear receptor- and cell-specific in vivo role for MED1 LxxLL motifs, through Mediator-ER(alpha) interactions, in mammary gland development. [Proc Natl Acad Sci U S A]

Function-Based Gene Identification Using Enzymatically Generated Normalized shRNA Library and Massive Parallel Sequencing
As a general strategy for function-based gene identification, an shRNA library containing on average 150 shRNAs per gene was enzymatically generated from normalized (reduced-redundance) human cDNA. [Proc Natl Acad Sci U S A]

Retinoic Acid Mediates Regulation of Network Formation by COUP-TFII and VE-Cadherin Expression by TGF(Beta) Receptor Kinase in Breast Cancer Cells
This study demonstrates that of the endothelial-related genes induced by retinoic acid (RA) treatment, only a few were affected by knockdown of VE-cadherin, ruling it out as a regulator of the RA-induced endothelial genotypic switch. [PLoS ONE]

Epithelial-Mesenchymal Transition (EMT) in Tumor-Initiating Cells and Its Clinical Implications in Breast Cancer
Researchers review recent evidence of the involvement of epithelial-mesenchymal transition in breast cancer tumor-initiating cells, focusing on clinical studies. [J Mammary Gland Biol Neoplasia]

CLINICAL RESEARCH

Population-Based Study of the Risk of Second Primary Contralateral Breast Cancer Associated With Carrying a Mutation in BRCA1 or BRCA2
This study assessed the risk of subsequent contralateral breast cancer associated with carrying a BRCA1 or BRCA2 mutation. [J Clin Oncol]

Intratumor Heterogeneity and Precision of Microarray-Based Predictors of Breast Cancer Biology and Clinical Outcome
Researchers investigate the impact of intratumor heterogeneity, a largely unstudied component of variance, on the performance of several microarray-based assays in breast cancer. [J Clin Oncol]

Effect of Changing Breast Cancer Incidence Rates on the Calibration of the Gail Model
The Gail model combines relative risks for five breast cancer risk factors with age-specific breast cancer incidence rates and competing mortality rates to predict risk of invasive breast cancer over a given time period. Researchers evaluated the model’s calibration in two recent cohorts. [J Clin Oncol]

Effect of Zoledronic Acid on Disseminated Tumour Cells in Women With Locally Advanced Breast Cancer: An Open Label, Randomised, Phase II Trial

The aim of this study was to assess the effect of zoledronic acid on clearance of disseminated tumor cells from the bone marrow in women undergoing neoadjuvant chemotherapy for breast cancer. [Lancet Oncol]


INDUSTRY NEWS

US Seeks to Make Science Free For All
Moves to make research funded by the US government available to everyone could mark a turning point in a publishing revolution. [Nature News]

Eisai Submits Regulatory Applications for Investigational Anticancer Agent Eribulin Mesylate (E7389) in Japan, the United States and Europe
Eisai Co., Ltd. announced that it has submitted regulatory applications for approval of eribulin mesylate for the treatment of locally advanced or metastatic breast cancer to health authorities in Japan, the United States and Europe. [Eisai Co., Ltd. Press Release]



POLICY NEWS

Enhancing Peer Review: Updated Processes for the Review of All Ruth L. Kirschstein National Research Service Award Fellowship Applications (NOT-OD-10-071) [National Institutes of Health, United States]

NIH Will Require the Electronic Submission of Appointment Forms and Termination Notices via xTrain for Research Training, Fellowship, Education, and Career Awards Beginning January 2011 (NOT-OD-10-072) [National Institutes of Health, United States]

Small Business Innovation Research Award Levels Adjusted to $150,000 (Phase I) and $1,000,000 (Phase II) (NOT-OD-10-079) [National Institutes of Health, United States]

Notice of Change in Expiration Date for Program Announcement on Bioengineering Research Partnerships (PAR-07-352) (NOT-EB-10-001) [National Institutes of Health, United States]

Revision of the Requirements for Constituent Materials (Docket No. FDA-2010-N-0099) [Food and Drug Administration, United States]

Voting and Nonvoting Consumer Representative Members on Public Advisory Committees and Panels; Notice of Public Meeting (Docket No. FDA-2010-N-0001) [Food and Drug Administration, United States]

Determination of Regulatory Review Period for Purposes of Patent Extension; LUSEDRA (Docket Nos. FDA-2009-E-0202 and FDA-2009-E-0204) [Food and Drug Administration, United States]

Revision of Organization and Conforming Changes to Regulations (Docket No. FDA-2010-N-0148) [Food and Drug Administration, United States]

Administrative Practices and Procedures; Good Guidance Practices; Technical Amendment (Docket No. FDA-1999-N-3539) [Food and Drug Administration, United States]

2010 Biological License Application Supplement Noteworthy Approvals [Food and Drug Administration, United States]



EVENTS

34th Annual Symposium of the American Society of Breast Disease (ASBD)
April 16-17, 2010
New York City, United States

American Association for Cancer Research (AACR) 101st Annual Meeting 2010
April 17-21, 2010
Washington, DC, United States

BIT’s 3rd Annual World Cancer Congress 2010 – Breast Cancer Conference
April 25-27, 2010
Shanghai, China

IMPAKT Breast Cancer Conference
May 6-8, 2010
Brussels, Belgium

Breast Cancer Research 2010 Conference
May 18, 2010
London, United Kingdom

American Society of Clinical Oncology (ASCO) Annual Meeting 2010
June 4-8, 2010
Chicago, United States

Gordon Research Conference: Mammary Gland Biology
June 6-11, 2010
Lucca (Barga), Italy

12th Milan Breast Cancer Conference
June 16-18, 2010
Milan, Italy

The 21st Meeting of the European Association for Cancer Research (EACR)
June 26-29, 2010
Oslo, Norway

United Kingdom National Stem Cell Network (UKNSCN) Third Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom

2010 World Cancer Congress
August 18-21, 2010
Shenzhen, China

15th Congress of the European Society of Surgical Oncology (ESSO)
September 15-17, 2010
Bordeaux, France

35th European Society for Medical Oncology (ESMO) Congress
October 8-12, 2010
Milan, Italy

International Symposium on Breast Cancer Prevention: Nutrition, Communications, Public Policy
October 18-19, 2010
West Lafayette, United States

6th National Cancer Research Institute (NCRI) Conference
November 7-10, 2010
Liverpool, United Kingdom




JOB OPPORTUNITIES

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

 

Learn more about Mammary Cell News: Archives  |  Events  |  Subscribe  |  Contact Us